tirzepatide surmount-1 nejm 2022 weight loss percent First head-to-head trial compares and semaglutide - Results are in! Tirzepatide Treatment Leads to Weight
Description
Talk to your provider about possible side effects and whether this medication is right for you

Tirzepatide activates both GLP-1 and GIP receptors simultaneously, making it a dual agonist

How confident are you in the supply chain for any compounded medication you use

A common point of confusion involves the 5 mg pen and the injector button

Long-term incidence of gallstone disease after bariatric surgery: results from the nonrandomized controlled Swedish Obese Subjects study

doi: 10.1002/oby.20340
